GH Research’s lead candidate GH001, an inhaled mebufotenin therapy for treatment-resistant depression, delivered compelling Phase 2b results. In the GH001-TRD-201 trial, patients receiving a single dose regimen experienced a mean 15.5-point reduction in MADRS score versus placebo by Day 8 (p<0.0001). Six-month follow-up data showed a 73% remission rate in the active treatment arm, with many subjects maintaining symptom relief after just one or two administrations. The trial reported a favorable safety profile, with no serious drug-related adverse events and only mild transient side effects, underscoring the potential of infrequent dosing to reshape the TRD treatment paradigm.

As of the latest financial report, GH Research holds $293.9 million in cash and equivalents. With an average quarterly operating burn rate of approximately $14 million, management projects financial runway extending beyond five years without additional capital raises. The company’s disciplined cost structure has limited overhead and prioritized R&D spend on GH001, preserving capital while advancing regulatory milestones and scaling for pivotal studies.

GH Research will announce the status of its Investigational New Drug (IND) application for GH001 with the U.S. Food and Drug Administration on January 5, 2026 at 7:00 a.m. EST. A positive IND clearance will greenlight the global pivotal Phase 3 program in treatment-resistant depression, which is designed to enroll up to 300 patients across North America and Europe. The Phase 3 design incorporates the same primary endpoint—MADRS change at Day 8—with interim safety reviews scheduled after the first 50 subjects. Investors will closely watch this announcement, as IND acceptance would catalyze partnerships, expand trial enrollment, and potentially accelerate a regulatory submission timeline.